Biotechnology Startup Funding 2025-2026

What are all the funding deals in the biotechnology market from August 2025 to July 2026?

The table below lists every disclosed equity round raised by pure-play biotechnology companies between August 2025 and July 2026. We count as “pure-play” biotechnology companies those applying modern biological science and engineering to create or improve medical and life-science outcomes.

Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors, and the announcement source.

How active has fundraising been in the biotechnology market?

As of July 2026, fundraising in the biotechnology market has been very active across the past 12 months. Companies raised 119 disclosed equity rounds and $15.65B combined, which works out to 10.82 deals per month.

The biotechnology market also showed consistent deal production. The median month had 11 disclosed rounds, and no month in the dataset fell below 4 disclosed rounds.

Dollar activity was large but uneven. Average capital raised per month was $1.42B, while the median month reached $1.37B, which confirms that large financings appeared regularly.

The busiest months were October 2025 with 17 deals, December 2025 with 16 deals, and June 2026 with 15 deals. On capital, May 2026 led with $2.36B, largely because of the Isomorphic Labs round.

How concentrated has fundraising been in the biotechnology market?

As of July 2026, fundraising in the biotechnology market is concentrated, but not entirely dependent on one winner. Over the past 12 months, the largest deal represents 13.42% of capital, the top 3 deals reach 18.50%, and the top 10 reach 32.62%.

The Isomorphic Labs Series B is the largest round at $2.10B. It is a major outlier, but it does not define the whole biotechnology market by itself.

The top 10 deals total roughly one-third of disclosed capital. That means two-thirds of funding still sits outside the largest 10 transactions, spread across many $50M to $200M rounds.

This concentration profile is different from a market where one or two mega-deals create the entire headline. The biotechnology market has outliers, but it also has real breadth underneath them.

How much of the biotechnology funding signal is driven by outliers?

As of July 2026, outliers matter in the biotechnology market, but they do not fully control the funding signal. Over the past 12 months, the top 5 deals account for 22.61% of disclosed capital, while the top 10 account for 32.62%.

The largest outliers include Isomorphic Labs at $2.10B, NewLimit at $435M, Tubulis at $361M, Ollin Biosciences at $330M, and Kriya Therapeutics at $313M. These rounds show how large biotech checks can become when platform ambition meets clinical or strategic relevance.

Still, the market is not just a top-five story. A large number of companies raised between $50M and $200M, which gives the biotechnology market a wider middle than many emerging technology markets.

The better reading rule is not to ignore outliers, but to separate platform-defining rounds from baseline activity. In this dataset, baseline activity is already large because the median round is $100M.

Is the biotechnology market broad with many targets, or narrow with few fundable companies?

As of July 2026, the biotechnology market is broad within large disclosed rounds, not narrow. Over the past 12 months, 119 disclosed deals were raised by 116 unique companies, which means the funding base is not limited to a few repeat raisers.

Only a small number of companies raised more than once during the window. Lila Sciences, Ollin Biosciences, and Syneron Bio each appear twice, while most companies appear only once.

The breadth is also visible across stages. Series A contributed 41 deals and Series B contributed 44 deals, so capital is flowing into both formation-stage companies and companies moving through validation.

However, this is not a broad small-startup dataset. Every round is $50M or larger, which means the visible biotechnology market mainly captures companies able to support institutional-scale clinical or platform programs.

Is biotechnology mostly an early-stage formation market or a late-stage scaling market?

As of July 2026, the biotechnology market is mostly an early-private formation and validation market. Over the past 12 months, Seed, Series A, and Series B together captured $11.30B, or 72.21% of disclosed capital.

Series B is the strongest stage by both deal count and capital. It accounts for 44 deals and $6.54B, which suggests investors prefer companies past formation risk but still before late-stage valuation discipline.

Series A is also unusually large in the biotechnology market. The stage produced 41 deals and $4.68B, with an average round size of $114.1M.

Late-stage rounds were selective rather than absent. Series C, Series D+, and Growth Equity together raised $3.12B, often for companies with stronger clinical, platform, or asset-readiness signals.

Which categories attract the most investor attention in biotechnology?

As of July 2026, Therapeutics Discovery Platforms attract the most investor attention in biotechnology. Over the past 12 months, the category captured 90 of 119 deals and $11.93B, equal to 76.23% of disclosed capital.

This dominance is not only a function of a few large outliers. Therapeutics Discovery Platforms represent 75.63% of deals and 76.23% of capital, so the category is almost perfectly aligned on volume and dollars.

Gene Editing Companies are the second-largest category with 16 deals and $1.93B. The category remains fundable, especially when companies can explain delivery, durability, or platform scalability.

Cell Therapy Developers and Synthetic Biology Platforms are smaller by count. Cell therapy has 9 deals and $855M, while synthetic biology has only 4 deals but $938M, making it much heavier per deal.

Which categories attract disproportionately large checks in the biotechnology market?

As of July 2026, Synthetic Biology Platforms attract disproportionately large checks in the biotechnology market. Over the past 12 months, they represented only 3.36% of deals but 5.99% of capital, giving the category a 1.78 capital-to-deal ratio.

The category’s average deal size is $234.5M and its median is $175M. That is higher than Therapeutics Discovery Platforms, Gene Editing Companies, and Cell Therapy Developers.

This pattern reflects how synthetic biology platform companies are being funded. Lila Sciences and NewLimit were financed like infrastructure-scale or platform-scale bets, not like conventional single-asset biotech startups.

Cell Therapy Developers show the opposite pattern. They account for 7.56% of deals but only 5.46% of capital, which suggests the biggest checks shifted toward broader therapeutics, AI discovery, and genetic medicine platforms.

Which geographies matter most for fundraising in the biotechnology market?

As of July 2026, North America matters most for biotechnology fundraising. Over the past 12 months, the region accounted for 84 deals and $10.06B, or 64.27% of disclosed capital.

North America’s dominance comes mainly from volume. It holds 70.59% of deals but 64.27% of dollars, so it is the deepest ecosystem rather than the richest geography per deal.

Europe is the second-largest geography by capital, with 18 deals and $3.98B. Its average round size is $221.2M, the highest of any region in the dataset.

Asia-Pacific contributed 17 deals and $1.61B. The region remains relevant for clinical assets and platform innovation, but its average round size of $94.8M is lower than North America and Europe.

Is biotechnology a market of small experiments or scaled financings?

As of July 2026, biotechnology is a market of scaled financings in this disclosed dataset. Over the past 12 months, all 119 disclosed rounds were $50M or larger, and the median round size was $100M.

This size distribution matters because it changes how the dataset should be interpreted. The visible biotechnology market is not measuring small lab formation; it is measuring companies able to raise multi-year clinical or platform capital.

Megarounds above $100M were also common. There were 58 rounds above that threshold, representing 48.74% of all disclosed deals.

The average round size was $131.5M, but the median is more useful for reading the market. A $100M median shows that large checks were not rare exceptions; they were the normal visible funding unit.

Who are the investors that appear the most in biotechnology fundraising?

As of July 2026, the most frequent investors in biotechnology fundraising are specialized life-science funds, pharma venture arms, crossover investors, and large institutional platforms. Over the past 12 months, repeat names included RA Capital Management, OrbiMed, Forbion, Sanofi Ventures, ARCH Venture Partners, Novo Holdings, and Eli Lilly or Lilly Ventures.

Pharma venture arms are especially important signals. Sanofi Ventures, Pfizer Ventures, Johnson & Johnson Innovation, Novo Holdings, Eli Lilly or Lilly Ventures, and other strategic investors appeared across the disclosed syndicates.

Crossover and institutional investors also matter because many companies are raising for longer private runways. Names such as Janus Henderson, Fidelity, Wellington Management, Mubadala Capital, and Temasek suggest private rounds are partly replacing public-market financing windows.

One important caveat: round announcements rarely disclose how much each investor personally committed. So repeat-investor visibility should be read as syndicate participation, not as a precise dollar ranking.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.